For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Research and development | 14,645 | 9,487* | 2,419 | |
| General and administrative | 7,459 | 5,179* | 2,827 | |
| Total operating loss | 22,104 | 14,666* | 5,246 | |
| Interest income | 2,850 | 1,799* | 707 | |
| Realized gain on sale of marketable securities, net | 0 | 119* | 0 | |
| Loss on change in fair value of derivative instruments | 200 | -1,788* | 983 | |
| Total non-operating income | 3,050 | 130* | 1,690 | |
| Loss before income tax | -19,054 | -14,536* | -3,556 | |
| Income tax provision | 0 | 1* | 0 | |
| Net loss | -19,054 | -14,537 | -3,556 | |
| Basic EPS | -0.67 | -1.414 | -0.61 | |
| Diluted EPS | -0.67 | -1.414 | -0.61 | |
| Basic Average Shares | 28,241,701 | 10,283,428 | 5,806,862 | |
| Diluted Average Shares | 28,241,701 | 10,283,428 | 5,806,862 | |
LB PHARMACEUTICALS INC (LBRX)
LB PHARMACEUTICALS INC (LBRX)